Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4

被引:23
|
作者
Nakayama, Shin [1 ,2 ,3 ,4 ,5 ]
Amiry-Moghaddam, Mahmood [6 ]
Ottersen, Ole Petter [6 ]
Bhardwaj, Anish [1 ,2 ,3 ,4 ,7 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, Dept Anesthesiol, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Dept Perioperat Med, Portland, OR 97201 USA
[5] Univ Tsukuba, Dept Anesthesiol, Fac Med, Tsukuba, Ibaraki, Japan
[6] Univ Oslo, Inst Basic Med Sci, Oslo, Norway
[7] Univ Texas Med Branch, Dept Neurol, 9-128 John Sealy Annex,Route 0539,301 Univ Blvd, Galveston, TX 77555 USA
关键词
Conivaptan; Global cerebral ischemia; Cardiac arrest; Cerebral edema; Aquaporins; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; BLOOD-BRAIN-BARRIER; EXPERIMENTAL STROKE; HYPERTONIC SALINE; NERVOUS-SYSTEM; WATER-CONTENT; RAT-BRAIN; OSMOTHERAPY; MICE; ISCHEMIA;
D O I
10.1007/s12028-015-0236-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background Cerebral edema is a major cause of mortality following cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). Arginine vasopressin (AVP) and water channel aquaporin-4 (AQP4) have been implicated in the pathogenesis of CA-evoked cerebral edema. In this study, we examined if conivaptan, a V-1a and V-2 antagonist, attenuates cerebral edema following CA/CPR in wild type (WT) mice as well as mice with targeted disruption of the gene encoding alpha-syntrophin (alpha-syn(-/-)) that demonstrate diminished perivascular AQP4 pool. Methods Isoflurane-anesthetized adult male WT C57Bl/6 and alpha-syn(-/-) mice were subjected to 8 min CA/CPR and treated with either bolus IV injection (0.15 or 0.3 mg/kg) followed by continuous infusion of conivaptan (0.15 mg/kg/day or 0.3 mg/kg/day), or vehicle infusion for 48 h. Serum osmolality, regional brain water content, and blood-brain barrier (BBB) disruption were determined at the end of the experiment. Sham-operated mice in both strains served as controls. ResultsTreatment with conivaptan elevated serum osmolality in a dose-dependent manner. In WT mice, conivaptan at 0.3 mg dose significantly attenuated regional water content in the caudoputamen (81.0 +/- A 0.5 vs 82.5 +/- A 0.4 % in controls; mean +/- A SEM) and cortex (78.8 +/- A 0.2 vs 79.4 +/- A 0.2 % in controls), while conivaptan at 0.15 mg was not effective. In alpha-syn(-/-) mice, conivaptan at 0.3 mg dose did not attenuate water content compared with controls. Conivaptan (0.3 mg/kg/day) attenuated post-CA BBB disruption at 48 h in WT mice but not in alpha-syn(-/-) mice. Conclusions Continuous IV infusion of conivaptan attenuates cerebral edema and BBB disruption following CA. These effects of conivaptan that are dependent on the presence of perivascular pool of AQP4 appear be mediated via its dual effect on V-1 and V-2 receptors.
引用
收藏
页码:273 / 282
页数:10
相关论文
共 40 条
  • [21] Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
    Mondritzki, T. Thomas
    Boehme, P.
    Sandner, P.
    Dinh, W.
    Hueser, J.
    Truebel, H.
    Kolkhof, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 335 - 335
  • [22] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, C
    Bichet, D
    Udelson, JE
    Ghazzi, MM
    Selaru, P
    Chartier, K
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [23] Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise
    Balling, Louise
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soren
    Goldsmith, Steven R.
    Gustafsson, Finn
    AMERICAN HEART JOURNAL, 2018, 203 : 101 - 104
  • [24] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, CA
    Ghazzi, MM
    Selaru, P
    Bichet, DG
    Chartier, KK
    Udelson, JE
    CIRCULATION, 2000, 102 (18) : 535 - 535
  • [25] Efficacy and safety of oral conivaptan:: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Ghali, Jalal K.
    Koren, Michael J.
    Taylor, James R.
    Brooks-Asplund, Esther
    Fan, Kaisheng
    Long, Walker A.
    Smith, Neila
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2145 - 2152
  • [26] Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
    Yatsu, T
    Tomura, Y
    Tahara, A
    Wada, K
    Kusayama, T
    Tsukada, J
    Tokioka, T
    Uchida, W
    Inagaki, O
    Iizumi, Y
    Tanaka, A
    Honda, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (03) : 239 - 246
  • [27] Haemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist, in patients with advanced heart failure
    Udelson, J
    Smith, WB
    Hendrix, G
    Painchaud, C
    Ghazzi, MM
    Thomas, I
    Ghali, J
    Selaru, P
    Pressler, M
    Konstam, M
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [28] Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, MM
    Thomas, I
    Ghali, JK
    Selaru, P
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2000, 102 (18) : 593 - 593
  • [29] Effect of Small Molecule Vasopressin V1a and V2 Receptor Antagonists on Brain Edema Formation and Secondary Brain Damage following Traumatic Brain Injury in Mice
    Krieg, Sandro M.
    Sonanini, Sebastian
    Plesnila, Nikolaus
    Trabold, Raimund
    JOURNAL OF NEUROTRAUMA, 2015, 32 (04) : 221 - 227
  • [30] Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients
    Smith, WB
    Russell, S
    Ghali, JK
    Painchaud, CA
    Selaru, P
    Ghazzi, MM
    Konstam, MA
    Udelson, JE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 172A - 173A